Syneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops intelligent platform-driven macrocyclic peptide drug discovery
Develops next-generation T-cell engager therapies for cancer and autoimmune diseases
Helps teams build deploy and operate production-grade AI applications and agentic workflows
Pitching 5Y Capital? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room